Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Total Voting Rights

2 Jan 2025 15:00

RNS Number : 9716R
GSK PLC
02 January 2025
 

GSK plc

 

Total Voting Rights and Capital

 

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

 

The Company's issued share capital as at 31 December 2024 consisted of 4,314,303,734 shares of 31 ¼ pence each ('Ordinary Shares'), of which 169,171,155 Ordinary Shares were held in Treasury.

 

Therefore, the total number of voting rights in the Company is 4,145,132,579. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Notifications may be sent to company.secretary@gsk.com.

 

 

V A Whyte

Company Secretary

 

2 January 2025

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBSGDBUUGDGUD
Date   Source Headline
12th Dec 20243:30 pmRNSDirector/PDMR Shareholding
9th Dec 20246:29 pmRNSOverall survival data presented for Blenrep
9th Dec 20247:05 amRNSBlenrep combination China filing acceptance
9th Dec 20247:00 amRNSNucala COPD submission accepted by US FDA
5th Dec 20247:00 amRNSZhifei China collaboration revised and extended
2nd Dec 20243:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20243:00 pmRNSTotal Voting Rights
27th Nov 20247:00 amRNSGSK liquid meningitis vaccine authorised in EU
25th Nov 20247:00 amRNSBlenrep combinations accepted for US FDA review
22nd Nov 20247:00 amRNSJapan approves first RSV vaccine for adults 50-59
19th Nov 20243:30 pmRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSGLISTEN Trial of Linerixibat Meets Endpoint
14th Nov 20247:00 amRNSGSK announces overall survival results for Blenrep
13th Nov 20243:00 pmRNSBlock listing Interim Review
12th Nov 20243:30 pmRNSDirector/PDMR Shareholding
11th Nov 20243:01 pmRNSGSK publishes provisional 2025 dividend dates
1st Nov 20243:00 pmRNSTotal Voting Rights
30th Oct 20242:29 pmRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNS3rd Quarter Results
24th Oct 20247:00 amRNSNew positive Arexvy data in younger adults at risk
17th Oct 20243:30 pmRNSDirector/PDMR Shareholding
16th Oct 20244:09 pmRNSDirector/PDMR Shareholding
16th Oct 20247:00 amRNSFDA accepts new drug application for gepotidacin
14th Oct 20243:30 pmRNSDirector/PDMR Shareholding
14th Oct 20247:00 amRNSPositive results of ANCHOR trials of depemokimab
11th Oct 20243:33 pmRNSDirector/PDMR Shareholding
10th Oct 20243:30 pmRNSDirector/PDMR Shareholding
9th Oct 20245:48 pmRNSZantac (ranitidine) litigation settlements
8th Oct 202411:45 amRNSPositive efficacy data of Arexvy over 3 seasons
1st Oct 20243:00 pmRNSTotal Voting Rights
24th Sep 20243:30 pmRNSDirector/PDMR Shareholding
24th Sep 20247:00 amRNSPositive EU opinion for GSK liquid Menveo vaccine
18th Sep 20241:20 pmRNSStatement: Zantac (ranitidine) litigation
17th Sep 20247:00 amRNSJapan Filing Acceptance: Blenrep Multiple Myeloma
13th Sep 20247:00 amRNSChina Breakthrough Therapy Designation for Blenrep
12th Sep 20243:30 pmRNSDirector/PDMR Shareholding
12th Sep 20247:00 amRNSPositive mRNA flu vaccine Phase II headline data
11th Sep 20245:27 pmRNSStatement: Zantac (ranitidine) litigation
11th Sep 20243:30 pmRNSChange of Registered Office
11th Sep 20247:00 amRNSUpdate on phase I/II therapeutic HSV vaccine trial
9th Sep 20242:30 pmRNSDepemokimab late-breaking data presented at ERS
6th Sep 20243:30 pmRNSDirector/PDMR Shareholding
6th Sep 20247:00 amRNSPositive Phase III results for Nucala in COPD
2nd Sep 20243:00 pmRNSTotal Voting Rights
29th Aug 20247:00 amRNSEMA approval on Arexvy for 50-59 at risk
28th Aug 20247:10 amRNSSENKU Designation for Bepirovirsen in Japan
28th Aug 20247:05 amRNSNucala approved in Japan for use in CRSwNP
28th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
21st Aug 20243:30 pmRNSDirector/PDMR Shareholding
20th Aug 20243:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.